• Stephen S. Gottlieb


Diuretic medications are deemed essential for the treatment of most patients with congestive heart failure (CHF). The underlying abnormality present in patients with heart failure leads to neurohormonal activation and salt and water retention. Medicines that cause increased sodium, and therefore water, excretion can be extremely effective. Indeed, symptoms of CHF may be completely relieved by this simple and inexpensive intervention. However, the adverse consequences associated with the use of diuretic medications are rarely considered. Knowledge of both potential problems and benefits can lead to safer and more effective use of these agents.


Heart Failure Congestive Heart Failure Mitral Regurgitation Heart Failure Patient Atrial Natriuretic Peptide 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Achhammer I, Podszuz T. Effect of furosemide on pulmonary and cardiac haemodynamics after treatment of chronic heart failure. In: Puschett JB, Greenberg A, eds. Diuretics III: Chemistry, Pharmacology, and Clinical Applications. New York: Elsevier Science Publishing Co; 1990:331–333.Google Scholar
  2. 2.
    Stampfer M, Epstein SE, Beiser GD, Braunwald E. Hemodynamic effects of diuresis at rest and during intense upright exercise in patients with impaired cardiac function. Circulation. 1968;37:900–911.PubMedGoogle Scholar
  3. 3.
    Dikshit K, Vyden JK, Forrester JS, Chatterjee K, Prakash R, Swan HJC. Renal and extrarenal hemodynamic effects of furosemide in congestive heart failure after acute myocardial infarction. N Engl J Med. 1973;288:1087–1090.PubMedCrossRefGoogle Scholar
  4. 4.
    Francis GS, Siegel RM, Goldsmith SR, Olivari MT, Levine TB, Cohn JN. Acute vasoconstrictor response to intravenous furosemide in patients with chronic congestive heart failure. Ann Intern Med. 1985;103:1–6.PubMedGoogle Scholar
  5. 5.
    Biddle TL, Yu PN. Effect of furosemide on hemodynamics and lung water in acute pulmonary edema secondary to myocardial infarction. Am J Cardiol. 1979;43:86–90.PubMedCrossRefGoogle Scholar
  6. 6.
    Hutcheon D, Nemeth E, Quinlan D. The role of furosemide alone or in combination with digoxin in the relief of symptoms of congestive heart failure. J Clin Pharmacol. 1980;20:59–68.PubMedGoogle Scholar
  7. 7.
    Wilson JR, Reichek N, Dunkman WB, Goldberg S. Effect of diuresis on the performance of the failing left ventricle in man. Am J Med. 1981;70:234–239.PubMedCrossRefGoogle Scholar
  8. 8.
    Perloff JK, Roberts WC. The mitral apparatus: functional anatomy and mitral regurgitation. Circulation. 1972;46:227–239.PubMedGoogle Scholar
  9. 9.
    Stevenson LW, Dadourian BJ, Child JS, Clark SH, Laks H. Mitral regurgitation after cardiac transplantation. Am J Cardiol. 1987;60:119–122.PubMedCrossRefGoogle Scholar
  10. 10.
    Stevenson LW, Brunken RC, Belil D, et al. Afterload reduction with vasodilators and diuretics decreases mitral regurgitation during upright exercise in advanced heart failure. J Am Coll Cardiol. 1990;15:174–180.PubMedCrossRefGoogle Scholar
  11. 11.
    Ramirez A, Abelmann WH. Hemodynamic effects of diuresis by ethacrynic acid. Arch Intern Med. 1968;121:320–326.PubMedCrossRefGoogle Scholar
  12. 12.
    MacGregor CD, Covell JW, Mahler F, Dilley RB, Rose J Jr. Relations between afterload, stroke volume, and the descending limb of Starling’s curve. Am J Physiol. 1975;227:884–890.Google Scholar
  13. 13.
    Ross J Jr, Sonnenblick EH, Taylor RR, Spotnitz HM, Covell JW. Diastolic geometry and sarcomere length in the chronically dilated canine left ventricle. Circ Res. 1971;28:49–61.PubMedGoogle Scholar
  14. 14.
    Nechwatal W, Stange A, Sigel H, et al. Der Einfluss von Piretanid auf die zentrale Hamodynamik und Belastungstoleranz von Patienten mit angina pectoris. Herz Kreislauf. 1982;14:91–96.Google Scholar
  15. 15.
    Ross J Jr. The assessment of myocardial performance in man by hemodynamic and cineangiographic technics. Am J Cardiol. 1969;23:511–515.PubMedCrossRefGoogle Scholar
  16. 16.
    Keeton TK, Campbell WB. The pharmacologic alteration of renin release. Pharmacol Rev. 1980;32:81–227.PubMedGoogle Scholar
  17. 17.
    Broqvist M, Dahlstrom U, Karlberg BE, Karlsson E, Marklund T. Neuroendocrine response in acute heart failure and the influence of treatment. Eur Heart J. 1989;10:1075–1083.PubMedGoogle Scholar
  18. 18.
    Francis GS, Benedict C, Johnstone DE, et al. Comparison of neuroendocrine activation in patients with left ventricular dysfunction with and without congestive heart failure: a substudy of the Studies of Left Ventricular Dysfunction (SOLVD). Circulation. 1990;82:1724–1729.PubMedCrossRefGoogle Scholar
  19. 19.
    Bayliss J, Norell M, Canepa-Anson R, Sutton G, Poole-Wilson P. Untreated heart failure: clinical and neuroendocrine effects of increasing diuretics. Br Heart J. 1987;57:17–22.PubMedCrossRefGoogle Scholar
  20. 20.
    Verho M, Heintz B, Nelson K, Kirsten R. The effects of piretanide on catecholamine metabolism, plasma renin activity and plasma aldosterone: a double-blind study versus furosemide in healthy volunteers. Curr Med Res Opin. 1985;7:461–467.CrossRefGoogle Scholar
  21. 21.
    Knight RK, Miall PA, Hawkins LA, Dacombe J, Edwrads CRW, Hamer J. Relation of plasma aldosterone concentration to diuretic treatment in patients with severe heart disease. Br Heart J. 1979;42:316–325.PubMedCrossRefGoogle Scholar
  22. 22.
    de Langen CDJ, van Gilst WH, de Graeff PA, Kingma JH, Wesseling H. Effects of the renin-angiotensin system on sustained ventricular tachycardia after myocardial infarction. Circulation. 1986;74:11–351.Google Scholar
  23. 23.
    Brilla CG, Janicki JS, Weber KT. Myocardial fibrosis in systemic hypertension: role of mineralocorticoids, dietary sodium and hypertension. Clin Res. 1990;38:868A.Google Scholar
  24. 24.
    Bayliss PH, DeBeer FC. Human plasma vasopressin response to potent loop-diuretic drugs. Eur J Clin Pharmacol. 1981;20:343–346.CrossRefGoogle Scholar
  25. 25.
    Genest J. The atrial natriuretic factor. Br Heart J. 1986;56:302–316.PubMedCrossRefGoogle Scholar
  26. 26.
    Edwards BS, Zimmerman RS, Burnett JC Jr. Atrial natriuretic factor: physiologic actions and implications in congestive heart failure. Cardiovasc Drugs Ther. 1987; 1:89–100.PubMedCrossRefGoogle Scholar
  27. 27.
    Schiffrin EL. Decreased density for binding sites of atrial natriuretic peptide on platelets of patients with severe congestive heart failure. Clin Sci. 1988;74:213–218.PubMedGoogle Scholar
  28. 28.
    Gottlieb 55, Kukin ML, Ahern D, Packer M. Prognostic importance of atrial natriuretic peptide in patients with chronic heart failure. J Am Coll Cardiol. 1989;13:1534–1539.PubMedCrossRefGoogle Scholar
  29. 29.
    Riegger GAJ, Eisner D, Kromer EP, et al. Atrial natriuretic peptide in congestive heart failure in the dog: plasma levels, cyclic guanosine monophosphate, ultra-structure of atrial myoendocrine cells, and hemodynamic, hormonal, and renal effects. Circulation. 1988;77:398–406.PubMedCrossRefGoogle Scholar
  30. 30.
    Johnston GD, Hiatt WR, Nies AS, Payne A, Murphy RC, Gerber JG. Factors modifying the early non-diuretic vascular effects of furosemide in man. Circ Res. 1983;53:630–635.PubMedGoogle Scholar
  31. 31.
    Green TP, Thompson TR, Johnson DE, Lock JE. Furosemide promotes patent ductus arteriosus in premature infants with the respiratory distress syndrome. N Engl J Med. 1983;308:743–748.PubMedCrossRefGoogle Scholar
  32. 32.
    Dorian B, Larrue J, Defeudis FV Salari H, Borgeat P, Braquet P. Activation of prostacyclin synthesis in cultured aortic smooth muscle cells by diuretic-antihypertensive drugs. Biochem Pharmacol. 1984;33:2265–2269.PubMedCrossRefGoogle Scholar
  33. 33.
    Multher RS, Potter DM, Bennett WM. Aspirin-induced depression of glomerular filtration rate in normal humans: role of sodium balance. Ann Intern Med. 1981;94:317–321.Google Scholar
  34. 34.
    Kao W, Gheorghiade M, Hall V, Goldstein S. Relation between plasma norepinephrine and response to medical therapy in congestive heart failure secondary to coronary artery disease or idiopathic dilated cardiomyopathy. Am J Cardiol. 1989;64:609–613.PubMedCrossRefGoogle Scholar
  35. 35.
    Packer M, Lee WH, Kessler PD, Gottlieb SS, Bernstein JL, Kukin ML. Role of neurohormonal mechanisms in determining surnval in patients with severe chronic heart failure. Circulation. 1987;75.TV-80–IV-92.Google Scholar
  36. 36.
    Abraham AS, Meshulam Z, Rosenmann D, Eylath U. Influence of chronic diuretic therapy on serum, lymphocyte and erythrocyte potassium, magnesium and calcium concentrations. Cardiology. 1988;75:17–23.PubMedCrossRefGoogle Scholar
  37. 37.
    Whyte KF, Whitesmith R, Reid JL. The effect of diuretic therapy on adrenaline-induced hypokalemia and hypo-magnesemia. Eur J Clin Pharmacol. 1988;34:333–337.PubMedCrossRefGoogle Scholar
  38. 38.
    Lipworth BJ, McDevitt DG, Struthers AD. Prior treatment with diuretic augments the hypokalemic and electrocardiographic effects of inhaled albuterol. Am J Med. 1989;86:653–657.PubMedCrossRefGoogle Scholar
  39. 39.
    Morgan DB, Davidson C. Hypokalemia and diuretics: an analysis of publications. Br Med J. 1980;280:905–908.PubMedCrossRefGoogle Scholar
  40. 40.
    Papademetriou V, Burris JF, Notargiacomo A, Fletcher RD, Freis ED. Thiazide therapy is not a cause of arrhythmia in patients with systemic hypertension. Arch Intern Med. 1988;148:1272–1276.PubMedCrossRefGoogle Scholar
  41. 41.
    Roden DM, Hoffman BF. Action potential prolongation and induction of abnormal automaticity by low quinidine concentrations in canine purkinje fibers: relationship of potassium and cycle length. Circ Res. 1985;56:857–867.PubMedGoogle Scholar
  42. 42.
    Steiness E, Olesen KH. Cardiac arrhythmias induced by hypokalemia and potassium loss during maintenance digoxin therapy. Br Heart J. 1976;38:167–172.PubMedCrossRefGoogle Scholar
  43. 43.
    Dyckner T, Helmers C, Lundman T, Wester PO. Initial serum potassium level in relation to early complications and prognosis in patients with acute myocardial infarction. Acta Med Scand. 1975;197:207–210.PubMedCrossRefGoogle Scholar
  44. 44.
    Pelleg A, Mitamura H, Price R, et al. Extracellular potassium ion dynamics and ventricular arrhythmias in the canine heart. J Am Coll Cardiol. 1989;13:941–950.PubMedCrossRefGoogle Scholar
  45. 45.
    Packer M, Lee WH. Provocation of hyper- and hypokalemic sudden death during treatment with and withdrawal of converting enzyme inhibition in severe chronic congestive heart failure. Am J Cardiol. 1986;57:347–348.PubMedCrossRefGoogle Scholar
  46. 46.
    Gottlieb SS. Importance of magnesium in congestive heart failure. Am J Cardiol. 1989;63:39G–42G.PubMedCrossRefGoogle Scholar
  47. 47.
    Ralston MA, Murnane MR, Kelley RE, Altschuld RA, Unverferth DV, Leier CV. Magnesium content of serum, circulating mononuclear cells, skeletal muscle, and myocardium in congestive heart failure. Circulation. 1989;80:573–580.PubMedCrossRefGoogle Scholar
  48. 48.
    Dorup I, Skajaa K, Clausen T, Kjeldsen K. Reduced concentrations of potassium, magnesium, and sodium-potassium pumps in human skeletal muscle during treatment with diuretics. Br Med J. 1988;296:455–458.CrossRefGoogle Scholar
  49. 49.
    Lim P, Jacob E. Magnesium deficiency In patients on long-term diuretic therapy for heart failure. Br Med J. 1972;3:60–62.CrossRefGoogle Scholar
  50. 50.
    Mulder H, Schopman W, van der Lely AJ, Schopman W Sr. Acute change in plasma renin activity, plasma aldosterone concentration and plasma electrolyte concentrations following furosemide administration in patients with congestive heart failure —interrelationships and diuretic response. Horm Metab Res. 1987; 19:80–83.PubMedCrossRefGoogle Scholar
  51. 51.
    Girchev RA, Natcheff ND. Excretory function after renal denervation and administration of diuretic to unanesthetized dogs. Biomed Biochim Acta. 1988;6:507–514.Google Scholar
  52. 52.
    Sheehan J, White A. Diuretic-associated hypomag-nesemia. Br Med J. 1982;285:1157–1159.CrossRefGoogle Scholar
  53. 53.
    Polimeni PI, Page E. Magnesium in heart muscle. Circ Res. 1973;33:367–374.PubMedGoogle Scholar
  54. 54.
    Dagirmanjian R, Goldman H. Magnesium deficiency and distribution of blood in the rat. Am J Physiol. 1970; 218:1464–1467.PubMedGoogle Scholar
  55. 55.
    Ghani MF, Rabah M. Effect of magnesium chloride on electrical stability of the heart. Am Heart J. 1977;94:600–602.PubMedCrossRefGoogle Scholar
  56. 56.
    Flink EB. Hypomagnesemia in patients receiving digitalis. Arch Intern Med. 1985;145:625–626.PubMedCrossRefGoogle Scholar
  57. 57.
    Bailie DS, Inoue H, Kaseda 5, Ben-David J, Zipes DP. Magnesium suppression of early afterdepolarizations and ventricular tachyarrhythmias induced by cesium in dogs. Circulation. 1988;6:1395–1402.Google Scholar
  58. 58.
    Iseri LT, Freed J, Bures AR. Magnesium deficiency and cardiac disorders. Am J Med. 1975;58:837–846.PubMedCrossRefGoogle Scholar
  59. 59.
    Ramee SR, White CJ, Svinarich JT, Watson TD, Fox RF. Torsades des pointe and magnesium deficiency. Am Heart J. 1985;109:823–828.Google Scholar
  60. 60.
    White RE, Hartzell HC. Magnesium ions in cardiac function regulator of ion channels and second messengers. Biochem Pharmacol. 1989;38:859–867.PubMedCrossRefGoogle Scholar
  61. 61.
    Shils ME. Experimental human magnesium deficiency. Medicine. 1969;48:61–85.PubMedCrossRefGoogle Scholar
  62. 62.
    Gottlieb SS, Baruch L, Kukin ML, Bernstein JL, Fisher ML, Packer M. Prognostic importance of the serum magnesium concentration in patients with congestive heart failure. J Am Coll Cardiol. 1990;16:827–831.PubMedCrossRefGoogle Scholar
  63. 63.
    Ralston MA, Murnane MR, Unverferth DV, Leier CV. Serum and tissue magnesium concentrations in patients with heart failure and serious ventricular arrhythmias. Ann Intern Med. 1990;113:841–846.PubMedGoogle Scholar
  64. 64.
    Anand IS, Ferrari R, Kalra GS, Wahi PL, Poole-Wilson PA, Haris PC. Edema of cardiac origin. Studies of body water and sodium, renal function, hemodynamic indexes, and plasma hormones in untreated congestive cardiac failure. Circulation. 1989;80:299–305.PubMedCrossRefGoogle Scholar
  65. 65.
    Gross P, Ketteler M, Hausmann C, et al. Role of diuretics, hormonal derangements, and clinical setting of hyponatremia in medical patients. Klin Wochenschrift. 1988;66:662–669.CrossRefGoogle Scholar
  66. 66.
    Kennedy RM, Earley LE. Profound hyponatremia resulting from a thiazide-induced decrease in urinary diluting capacity in a patient with primary polydypsia. N Engl J Med. 1970;282-1185–1186.PubMedCrossRefGoogle Scholar
  67. 67.
    Schrier RW, Berl T, Anderson RJ. Osmotic and nonosmotic control of vasopressin release. Am J Physiol. 1979;236:F321–F332.PubMedGoogle Scholar
  68. 68.
    Dzau VJ, Hollenberg NK. Renal response to Captopril in severe heart failure: role of furosemide in natriuresis and reversal of hyponatremia. Ann Intern Med. 1984; 100: 777–782.PubMedGoogle Scholar
  69. 69.
    Lee WH, Packer M. Prognostic importance of serum sodium concentration and its modification by converting-enzyme inhibition in patients with severe chronic heart failure. Circulation. 1986;73:257–267.PubMedCrossRefGoogle Scholar
  70. 70.
    White MG, van Gelder J, Estes G. The effect of loop diuretics on the excretion of Na+, Ca2+, Mg2+, and Cl-. J Clin Pharmacol. 1981;21:610–614.PubMedGoogle Scholar
  71. 71.
    Breslau N, Moses AM, Weiner IM. The role of volume contraction in the hypocalciuric action of chlorothiazide. Kidney Int. 1976;10:164–170.PubMedCrossRefGoogle Scholar
  72. 72.
    Marone C, Muggli F, Lahn W, Frey FJ. Pharmacokinetic and pharmacodynamic interaction between furosemide and metolazone in man. Eur J Clin Invest. 1985; 15: 253–257.PubMedCrossRefGoogle Scholar
  73. 73.
    Bristow MR, Schwartz HD, Binetti G, Harrison DC, Daniels JR. Ionized calcium and the heart: elucidation of in vivo concentration-response relationships in the open-chest dog. Circ Res. 1977;41:565–574.PubMedGoogle Scholar
  74. 74.
    Ginsburg R, Esserman LJ, Bristow MR. Myocardial performance and extracellular ionized calcium in a severely failing human heart. Ann Intern Med. 1983;98:603–606.PubMedGoogle Scholar
  75. 75.
    Ring-Larsen H, Henriksen JH, Wilken C, Clausen J, Pals H, Christensen NJ. Diuretic treatment in decompensated cirrhosis and congestive heart failure: effect of posture. Br Med J. 1986;292:1351–1353.CrossRefGoogle Scholar
  76. 76.
    Schuster CJ, Weil MH, Besso J, Carpio M, Henning RJ. Blood volume following diuresis induced by furosemide. Am J Med. 1984;76:585–592.PubMedCrossRefGoogle Scholar
  77. 77.
    Hook JB, Blatt AH, Brody MJ, Williamson HE. Effects of several saluretic-diuretic agents on renal hemodynamics. J Pharmacol Exp Ther. 1966;154:667–673.PubMedGoogle Scholar
  78. 78.
    Scherer B, Weber PC. Time-dependent changes in prostaglandin excretion in response to frusemide in man. Clin Sci. 1979;56:77–81.PubMedGoogle Scholar
  79. 79.
    Kim KE, Onesti G, Moyer J, Swartz C. Ethacrynic acid and furosemide: diuretic and hemodynamic effects and clinical uses. Am J Cardiol. 1971;27:407–415.PubMedCrossRefGoogle Scholar
  80. 80.
    Hricik DE. Captopril-induced renal insufficiency and the role of sodium balance. Ann Intern Med. 1985; 103: 222–223.PubMedGoogle Scholar
  81. 81.
    Sica DA, Gehr T. Diuretics in congestive heart failure. Cardiol Clin. 1989;7:87–96.PubMedGoogle Scholar
  82. 82.
    Puschett JB, Greenberg A, eds. The Diuretic Manual. New York: Elsevier; 1984.Google Scholar
  83. 83.
    Dirks JH, Sutton RAL, eds. Diuretics: Physiology, Pharmacology, and Clinical Use. Philadelphia: Saunders; 1986.Google Scholar
  84. 84.
    Puschett JB. Clinical pharmacologic implications in diuretic selection. Am J Cardiol. 1986;57:6A–13A.PubMedCrossRefGoogle Scholar
  85. 85.
    Tilstone WJ, Dargie H, Dargie EN, Morgan HG, Kennedy AC. Pharmacokinetics of metolazone in normal subjects and in patients with cardiac or renal failure. Clin Pharmacol Ther. 1976;16:322–329.Google Scholar
  86. 86.
    Brater DC, Day B, Burdette A, Anderson S. Bumetanide and furosemide in heart failure. Kidney Int. 1984;26: 183–189.PubMedCrossRefGoogle Scholar
  87. 87.
    Lawson DH, Gray JMB, Henry DA, Tilstone WJ. Continuous infusion of frusemide in refractory oedema. Br Med J. 1978;2:476.PubMedCrossRefGoogle Scholar
  88. 88.
    Nomura A, Yasuda H, Minami M, Akimoto T, Miyazaki K, Arita T. Effect of furosemide in congestive heart failure. Clin Pharmacol Ther. 1981;30:177–182.PubMedCrossRefGoogle Scholar
  89. 89.
    Beermann B, Groschinsky-Grind M. Pharmacokinetics of hydrochlorothiazide in patients with congestive heart failure. Br J Clin Pharmacol. 1979;7:579–583.PubMedGoogle Scholar
  90. 90.
    Nicholls MG, Espiner EA, Hughes H, Rohers T. Effect of potassium-sparing diuretics on the renin-angiotensin-aldosterone system and potassium retention in heart failure. Br Heart J. 1976;38:1025–1039.PubMedCrossRefGoogle Scholar
  91. 91.
    Waldorff S, Hansen PB, Egeblad H, et al. Interactions between digoxin and potassium-sparing diuretics. Clin Pharmacol Ther. 1983;33:418–423.PubMedCrossRefGoogle Scholar
  92. 92.
    Garay RP, Diez J, Nazaret C, Dagher G, Abitol JP. The interaction of canrenone with the Na+, K+ pump in human red blood cells. Arch Pharmacol. 1985;329:311–315.CrossRefGoogle Scholar
  93. 93.
    Finnegan TP, Spence JD, Cape RD. Potassium sparing diuretics: interaction with digoxin in elderly men. J Am Geriatr Soc. 1984;32:129–131.PubMedGoogle Scholar
  94. 94.
    Kiyingi A, Field MJ, Pawsel CC, Yiannikas J, Lawrence JR, Arter WJ. Metolazone in treatment of severe refractory congestive heart failure. Lancet. 1990;335:29–31.PubMedCrossRefGoogle Scholar
  95. 95.
    Ghose RR, Gupta SK. Synergistic actions of metolazone with “loop” diuretics. Br Med J. 1981;812:1432–1433.CrossRefGoogle Scholar
  96. 96.
    Pabico RC, Rogal GJ, McKenna BA, Richeson JF, Hood WB. Renal effects of dobutamine and dopamine in congestive heart failure. In Puschett JB, Greenberg A, eds. Diuretics III: Chemistry, Pharmacology, and Clinical Applications. New York: Elsevier Science Publishing Co; 1990:302–312.Google Scholar
  97. 97.
    L’Abbate A, Emdin M, Piacenti M, et al. Ultrafiltration: a rational treatment for heart failure. Cardiology. 1989;76:384–390.PubMedCrossRefGoogle Scholar
  98. 98.
    Puschett JB. Physiologic basis for the use of new and older diuretics in congestive heart failure. Cardiovasc Med. 1977;2:119–134.Google Scholar
  99. 99.
    Dirks JH, Sutton RAL, eds. Diuretics: Physiology, Pharmacology, and Clinical Use. Philadelphia: Saunders; 1986.Google Scholar

Copyright information

© Springer-Verlag New York, Inc. 1994

Authors and Affiliations

  • Stephen S. Gottlieb

There are no affiliations available

Personalised recommendations